“We look ahead to persevering with our manufacturing partnership with Samsung Biologics for our lead product candidate, cosibelimab, at the moment in a pivotal medical trial for metastatic cutaneous squamous cell carcinoma. Checkpoint is on monitor to report full topline outcomes from the pivotal trial in mid-2021,” mentioned James F. Oliviero, President and Chief Government Officer of Checkpoint. “This settlement gives Checkpoint entry to a top-tier manufacturing website for the long-term business provide of cosibelimab after potential regulatory approvals worldwide.”
“We’re extraordinarily happy with this prolonged partnership with Checkpoint to assist our consumer and make an affect by serving to broader affected person populations in want,” mentioned Dr. Tae Han Kim, CEO of Samsung Biologics. “As a dependable contract growth and manufacturing group (“CDMO”) service supplier, Samsung Biologics gives the very best high quality manufacturing for Checkpoint to help in its endeavor to deliver progressive remedies for sufferers throughout the globe.”
Samsung Biologics lately introduced it can break floor on its fourth plant this yr to start manufacturing actions within the latter half of 2022.